A- A A+

Different formulations of methadone and levomethadone in the management of Opioid Use Disorder.

Somaini L., Vecchio S., Salvatore D.F., Ercolini A., and Leonardi C.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, March 18, 2021

https://www.heroinaddictionrelatedclinicalproblems.org/download-article.php?idarticolodoi=Adoi0000318

Microdosing Case Study Series – Transferring from Methadone to Oral Buprenorphine

Cassells N., Hill D.R., Marr E., and Stewart E.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, December 4, 2020

Conclusions: The case studies demonstrate that the successful use of a microdose transition from methadone to oral buprenorphine is possible within a primary care setting with minimal side effects or discomfort and that this option could be explored further with other patients to improve therapeutic outcomes.

https://www.heroinaddictionrelatedclinicalproblems.org/download-article.php?idarticolodoi=Adoi0000302

A case study of methadone-induced delayed post-hypoxic leukoencephalopathy with improvement by antioxidant therapy. 

Hakamifard A, Hajiahmadi S, Khorvash F, Azish S. 

North Clin Istanb. 2020 Aug 31;8(1):106-108. doi: 10.14744/nci.2020.29795. PMID: 33629035; PMCID: PMC7881437.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881437/

Reasons for Increasing Daily Methadone Maintenance Dosage among Deceptive Patients: A Qualitative Study. 

Khosravi M, Kasaeiyan R. 

J Med Life. 2020 Oct-Dec;13(4):572-579. doi: 10.25122/jml-2020-0038. PMID: 33456609; PMCID: PMC7803314.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803314/

Methadone Suppresses Neuronal Function and Maturation in Human Cortical Organoids. 

Wu W, Yao H, Dwivedi I, Negraes PD, Zhao HW, Wang J, Trujillo CA, Muotri AR, Haddad GG. 

Front Neurosci. 2020 Nov 23;14:593248. doi: 10.3389/fnins.2020.593248. PMID: 33328864; PMCID: PMC7719724.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719724/

From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia. 

Raski M, Sutherland C, Brar R. 

Can Fam Physician. 2020 Nov;66(11):797-798. PMID: 33208417.

https://www.cfp.ca/content/66/11/797.long

The effect of methadone on depression among addicts: a systematic review and meta-analysis. 

Mohammadi M, Kazeminia M, Abdoli N, Khaledipaveh B, Shohaimi S, Salari N, Hosseinian-Far M. 

Health Qual Life Outcomes. 2020 Nov 23;18(1):373. doi: 10.1186/s12955-020-01599-3. PMID: 33225933; PMCID: PMC7681984.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681984/

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment. 

Abbaszadeh-Mashkani S, Hoque SS, Banafshe HR, Ghaderi A. 

Phytother Res. 2020 Oct 19. doi: 10.1002/ptr.6913. Epub ahead of print. PMID: 33078480.

Abstract

https://pubmed.ncbi.nlm.nih.gov/33078480/

Toward patient-tailored therapy in agonist opioid treatment: the role of psychopathology, craving behavioural covariates, stress reaction and methadone blood concentration. A case series

Maremmani A.G.I., Bacciardi S., Maremmani I., Della Rocca F., Lamanna F., Socci C., Cerrai E., Zallocco L., Cerniglia L., Cimino S., Giusti L., Lucacchini A., Protti M., Mercolini L., Perugi G., and Mazzoni M.R.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, October 2, 2020

https://www.heroinaddictionrelatedclinicalproblems.org/harcp-archives-doi-articles.php

A mixed‐methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community‐based care in England and Wales. 

Gibson, R., MacLeod, N., Donaldson, L. J., Williams, H., Hibbert, P., Parry, G., Bhatt, J., Sheikh, A., and Carson‐Stevens, A. (2020) 

Addiction, 115: 2066– 2076. doi.org/10.1111/add.15039.

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15039

Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. 

Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Greenland S, Gustafson P, Karim ME, McCandless LC, Maclure M, Platt RW, Siebert U, Socías ME, Tsui JI, Wood E, Nosyk B. 

BMJ Open. 2020 Sep 9;10(9):e036102. doi: 10.1136/bmjopen-2019-036102. PMID: 32912944; PMCID: PMC7482450.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482450/

Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug‐related poisoning deaths? A retrospective cohort study. 

Durand, L., O'Driscoll, D., Boland, F., Keenan, E., Ryan, B. K., Barry, J., Bennett, K., Fahey, T., and Cousins, G. (2020) 

Addiction, 115: 1867– 1877. doi.org/10.1111/add.15004. 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15004

Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use 

Ramli FF. 

[published online ahead of print, 2020 Aug 11]. Bosn J Basic Med Sci. 2020;10.17305/bjbms.2020.4897. doi:10.17305/bjbms.2020.4897

https://www.bjbms.org/ojs/index.php/bjbms/article/view/4897/1358

Comparing the Efficacy of Methadone and Tincture of Opium in Controlling Agitation Caused by Withdrawal Syndrome in Opium-Addicted Patients in the Intensive Care Unit: A Randomized Trial Study. 

Sohrevardi SM, Pournamdari M, Salimi R, Sarrafzadeh F, Ahmadinejad M. 

Addict Health. 2020;12(2):69-76. doi:10.22122/ahj.v12i2.259

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395929/

Methadone Inhibits Viral Restriction Factors and Facilitates HIV Infection in Macrophages.

Wang MR, Wu DD, Luo F, et al. 

Front Immunol. 2020;11:1253. Published 2020 Jul 3. doi:10.3389/fimmu.2020.01253

Methadone Inhibits Viral Restriction Factors and Facilitates HIV Infection in Macrophages.

Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of µ-Opioid Receptor 

Kapoor A, Provasi D, Filizola M. 

[published online ahead of print, 2020 Jul 17]. Mol Pharmacol. 2020;mol.119.119339. doi:10.1124/mol.119.119339

Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of µ-Opioid Receptor 

Methadone‐related deaths among youth and young adults in Sweden 2006–15.

Fugelstad, A., Bremberg, S., Hjelmström, P., and Thiblin, I. (2020) 

Addiction, doi.org/10.1111/add.15152.

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15152

An Efficient and Smooth Methadone-to-Buprenorphine Transition Protocol Utilizing a Transdermal Fentanyl Bridge and a Pharmacokinetic Inducer: The Stanciu Method. 

Stanciu CN, Gibson S, Teja N, Healey CJ. 

Cureus. 2020;12(5):e8310. Published 2020 May 27.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320635/

Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment 

Baldassarri SR, Beitel M, Zinchuk A, et al. 

[published online ahead of print, 2020 Jun 17]. Sleep Breath. 2020;10.1007/s11325-020-02123-z. doi:10.1007/s11325-020-02123-z

Abstract

https://pubmed.ncbi.nlm.nih.gov/32556918/

Contamination in Opium, Opium Tincture, and Methadone Oral Solution, in Iran. 

Rahimi M, Eshraghi MA, Shadnia S. Lead 

Addict Health. 2020;12(1):34-39. doi:10.22122/ahj.v12i1.258

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291899/

Scotland's 2009-2015 methadone-prescription cohort: quintiles for daily-dose of prescribed methadone and risk of methadone-specific death

Gao L, Robertson JR, Bird SM. 

[published online ahead of print, 2020 Jun 12]. Br J Clin Pharmacol. 2020;10.1111/bcp.14432.

Abstract

https://pubmed.ncbi.nlm.nih.gov/32530053/

Toward precision prescribing for methadone: Determinants of methadone deposition.

Talal AH, Ding Y, Venuto CS, Chakan LM, McLeod A, Dharia A, et al. (2020) 

PLoS ONE 15(4): e0231467. doi.org/10.1371/journal.pone.0231467

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231467

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

This updated Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA - Substance Abuse & Mental Health Services Administration, USA, Mai 2020)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006.pdf

The Use of the Methadone/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing.

McCarthy JJ, Graas J, Leamon MH, Ward C, Vasti EJ, Fassbender C.

J Addict Med. 2020 Feb 6. doi: 10.1097/ADM.0000000000000620. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/32032212

Sexual Inactivity in Methadone Maintenance Treatment Patients.

Ramli FF, Tg Abu Bakar Sidik TMI, Naina Mohamed I.

Int J Environ Res Public Health. 2020 Mar 18;17(6). pii: E1993. doi: 10.3390/ijerph17061993.

https://www.mdpi.com/1660-4601/17/6/1993

Differences in Gut Microbial Diversity are Driven by Drug Use and Drug Cessation by Either Compulsory Detention or Methadone Maintenance Treatment.

Li Q, Chen S, Liu K, Long D, Liu D, Jing Z, Huang X.

Microorganisms. 2020 Mar 13;8(3). pii: E411. doi: 10.3390/microorganisms8030411.

https://www.mdpi.com/2076-2607/8/3/411

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.

JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760032

Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment.

Sweeney MM, Antoine DG, Nanda L, Géniaux H, Lofwall MR, Bigelow GE, Umbricht A.

J Opioid Manag. 2019 Sep/Oct;15(5):367-374. doi: 10.5055/jom.2019.0526.

Abstract

https://jhu.pure.elsevier.com/en/publications/increases-in-body-mass-index-and-cardiovascular-risk-factors-duri

Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.

Callan J, Pytell J, Ross J, Rastegar DA.

J Addict Med. 2020 Jan 22. doi: 10.1097/ADM.0000000000000623. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31977358

Factors Related to Relapse in Patients with Substance-related Disorders under Methadone Maintenance Therapy: Decision Tree Analysis.

Moradinazar M, Farnia V, Alikhani M, Karyani AK, Rezaei S, Rezaeian S, Matin BK, Najafi F.

Oman Med J. 2020 Jan 23;35(1):e89. doi: 10.5001/omj.2020.07. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976887/

  1. Outcome of Patients With High Depressive Symptoms on Admission to Methadone Maintenance Treatment.
  2. Factors Associated with Sleep Disorders among Methadone-Maintained Drug Users in Vietnam.
  3. Health-Seeking Behavior for Erectile Dysfunction in Methadone Maintenance Treatment Patients.
  4. Preparation, Characterization and Dermal Delivery of Methadone.
  5. The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment.